24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
收藏DataCite Commons2025-12-16 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012258/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study assessed the safety, tolerability and efficacy of two doses of oral fingolimod compared to placebo on efficacy parameters in patients with relapsing-remitting multiple sclerosis (RRMS).
提供机构：
Vivli
创建时间：
2025-12-16
